170 related articles for article (PubMed ID: 28336299)
1. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
Arakawa H; Omote S; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
[TBL] [Abstract][Full Text] [Related]
2. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I
Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2.
Shu W; Ma L; Hu X; Zhang M; Chen W; Ma W; Huang J; Li J
Eur J Pharm Sci; 2020 Jan; 142():105153. PubMed ID: 31740393
[TBL] [Abstract][Full Text] [Related]
5. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
6. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.
Lepist EI; Zhang X; Hao J; Huang J; Kosaka A; Birkus G; Murray BP; Bannister R; Cihlar T; Huang Y; Ray AS
Kidney Int; 2014 Aug; 86(2):350-7. PubMed ID: 24646860
[TBL] [Abstract][Full Text] [Related]
7. Significance of Organic Anion Transporter 2 and Organic Cation Transporter 2 in Creatinine Clearance: Mechanistic Evaluation Using Freshly Prepared Human Primary Renal Proximal Tubule Cells.
Mathialagan S; Chung G; Pye K; Rodrigues AD; Varma MVS; Brown C
J Pharmacol Exp Ther; 2024 Jan; 388(1):201-208. PubMed ID: 37977812
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs.
George B; Wen X; Jaimes EA; Joy MS; Aleksunes LM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208557
[TBL] [Abstract][Full Text] [Related]
9. Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
Müller F; Weitz D; Derdau V; Sandvoss M; Mertsch K; König J; Fromm MF
Mol Pharm; 2017 Sep; 14(9):2991-2998. PubMed ID: 28708400
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the renal tubular transport of creatinine by activity-based protein profiling and transport kinetics.
Ma Y; Zhang M; Yang J; Zhu L; Dai J; Wu X
Eur J Pharm Sci; 2023 Jan; 180():106342. PubMed ID: 36435354
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Uremic Solutes on the Organic Cation Transporter 2.
Cheung KWK; Hsueh CH; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
J Pharm Sci; 2017 Sep; 106(9):2551-2557. PubMed ID: 28483424
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Inui KI
Eur J Pharm Sci; 2021 Mar; 158():105666. PubMed ID: 33296710
[TBL] [Abstract][Full Text] [Related]
13. Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats.
Shi R; Yang Y; Xu Z; Dai Y; Zheng M; Wang T; Li Y; Ma Y
Biopharm Drug Dispos; 2018 Jan; 39(1):47-58. PubMed ID: 29065218
[TBL] [Abstract][Full Text] [Related]
14. Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2.
Sandoval PJ; Morales M; Secomb TW; Wright SH
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F720-F734. PubMed ID: 31313952
[TBL] [Abstract][Full Text] [Related]
15. Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors.
Visentin M; Torozi A; Gai Z; Häusler S; Li C; Hiller C; Schraml PH; Moch H; Kullak-Ublick GA
Drug Metab Dispos; 2018 Aug; 46(8):1129-1136. PubMed ID: 29794161
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C; White-Koning M; Hennebelle I; Deluche T; Delmas C; Imbs DC; Chatelut E; Thomas F
Pharmacol Res; 2016 Aug; 110():89-95. PubMed ID: 27178732
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.
Sandoval PJ; Zorn KM; Clark AM; Ekins S; Wright SH
Mol Pharmacol; 2018 Sep; 94(3):1057-1068. PubMed ID: 29884691
[TBL] [Abstract][Full Text] [Related]
18. Plasma Membrane Cholesterol Regulates the Allosteric Binding of 1-Methyl-4-Phenylpyridinium to Organic Cation Transporter 2 (SLC22A2).
Hörmann S; Gai Z; Kullak-Ublick GA; Visentin M
J Pharmacol Exp Ther; 2020 Jan; 372(1):46-53. PubMed ID: 31624079
[TBL] [Abstract][Full Text] [Related]
19. The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?
Chu X; Bleasby K; Chan GH; Nunes I; Evers R
Drug Metab Dispos; 2016 Sep; 44(9):1498-509. PubMed ID: 26825641
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine.
Mathialagan S; Rodrigues AD; Feng B
J Pharm Sci; 2017 Sep; 106(9):2535-2541. PubMed ID: 28416419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
